However, perhaps not surprisingly, given the absence of a phenotype in Ripk3−/− mice, we found that neither the conditional deletion of Bcl-xL in myeloid cells nor the pharmacologic inhibition of BCL-XL after infection imparted any benefit to mice in terms of reduced bacterial burden. The gene discussed is RIPK3; the disease is infection.